Gynecomastia is the growth of true glandular breast tissue in men. It is not the same as the soft, diffuse fat over the chest that lean-bulking or a high body-fat percentage produces (that is often called pseudogynecomastia or lipomastia). Real gyno is a firm, sometimes tender, disc- or button-shaped mass sitting directly behind the nipple-areolar complex. You can usually feel the difference: glandular tissue is rubbery and concentrated under the nipple, whereas fat is soft and spread across the whole pec. This distinction matters because the two respond to completely different interventions — one to hormonal drugs, the other only to fat loss or liposuction.
The reason gyno is a recurring concern for anabolic steroid users is that the breast is an estrogen-responsive tissue, and several of the drugs in common use either raise estradiol or act on the same receptors that drive breast growth. Understanding which mechanism is at play in your case is the whole game, because a drug that fixes estrogen-driven gyno does nothing for the progestin-driven kind.
The two mechanisms: estrogen and progestin Most anabolic-steroid gyno is estrogen-driven. Aromatizable androgens such as testosterone are converted to estradiol by the aromatase enzyme in fat and other peripheral tissue. On a moderate testosterone cycle your estradiol can sit several times above the normal male range, and it is the ratio of estrogen to androgen signalling in breast tissue — not estrogen alone — that determines whether the gland proliferates. This is why gyno often appears early in a cycle before androgen levels have fully saturated, and why very lean people with low aromatase substrate sometimes escape it entirely.
The second mechanism is progestogenic. 19-nortestosterone compounds such as nandrolone-decanoate and trenbolone have activity at the progesterone receptor. Progestin does not by itself grow the breast the way estrogen does, but it appears to sensitise breast tissue to whatever estrogen is present, so 'nandrolone gyno' can develop even when estradiol looks only modestly elevated. The practical consequence is important: an aromatase inhibitor, which lowers estradiol, only partly addresses 19-nor gyno, because it does nothing about the progestogenic signal. People chasing this kind of gyno with escalating AI doses often crash their estrogen and still make no progress.
Prevention: stop it before the gland forms The cheapest and most effective time to deal with gyno is before any tissue has formed. Prevention has three parts. - Match your anti-estrogen to your dose and your history, not to a fixed protocol. Many people run testosterone with no gyno at all; the need scales with dose, aromatization rate, body fat and personal sensitivity. If you have never had a gyno problem on a given dose, you likely do not need a prophylactic drug. - If you do control estrogen, understand your two tool classes. An aromatase inhibitor (anastrozole roughly 0.25-0.5 mg every few days, or exemestane) lowers the estradiol you produce. A selective estrogen-receptor modulator, or SERM, such as tamoxifen (commonly 10-20 mg/day) blocks the estrogen receptor in breast tissue directly while leaving circulating estradiol intact. For pure gyno prevention the SERM is often the better first move because it protects the breast without the systemic downsides of crashing estrogen. - Act on early symptoms immediately. The first sign is usually itching, tenderness or a small tender lump under one nipple. Caught within days to a couple of weeks, a SERM will frequently reverse it. Left for months, the same tissue fibroses and stops responding.
Treating gyno that has already started Once you feel a lump, the window for a drug fix is open but closing. Tamoxifen is the best-evidenced medical treatment: in the breast-oncology and idiopathic-gynecomastia literature, tamoxifen at 10-20 mg/day produces at least partial regression in a majority of men with recent-onset gyno, with a meaningful minority getting complete resolution. It works best when the tissue is new, soft and tender — i.e. still actively proliferating rather than fibrosed.
Raloxifene, another SERM, is sometimes preferred for established pubertal gynecomastia. A small randomised paediatric comparison reported that raloxifene produced somewhat greater reduction in breast size than tamoxifen, and it is often dosed around 60 mg/day off-label. The human data are limited and mostly in adolescents rather than steroid users, so treat any claim of superiority as suggestive, not settled.
Aromatase inhibitors are commonly reached for but have the weakest treatment evidence. A placebo-controlled trial of anastrozole for pubertal gynecomastia failed to beat placebo on the primary endpoint of breast-size reduction. AIs are a reasonable tool for controlling the estrogen that is feeding new gland growth on cycle, but they are a poor tool for shrinking a mass that has already formed. If your gyno is 19-nor/progestin-driven, an AI is even less likely to help on its own; some users add cabergoline to address prolactin in that scenario, though the evidence that prolactin drives nandrolone gyno is thin.